Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (614) 614
Publication (49) 49
Patent (19) 19
Book Review (10) 10
Book Chapter (8) 8
Conference Proceeding (3) 3
Magazine Article (3) 3
Book / eBook (1) 1
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (348) 348
male (224) 224
index medicus (223) 223
infectious diseases (209) 209
adult (201) 201
female (194) 194
hiv (180) 180
hiv infections - drug therapy (166) 166
middle aged (164) 164
immunology (117) 117
hiv infections - complications (110) 110
virology (103) 103
viral load (89) 89
antiretroviral therapy (81) 81
hepatitis c (80) 80
human immunodeficiency virus--hiv (79) 79
treatment outcome (78) 78
hiv infections - virology (75) 75
human-immunodeficiency-virus (65) 65
aids (63) 63
cd4 lymphocyte count (62) 62
aged (61) 61
anti-hiv agents - therapeutic use (61) 61
infection (61) 61
risk factors (59) 59
antiviral agents - therapeutic use (58) 58
hiv infections - immunology (58) 58
drug therapy (57) 57
drug therapy, combination (57) 57
hiv infection (57) 57
hepatitis (54) 54
young adult (54) 54
antiviral agents (52) 52
pharmacology & pharmacy (52) 52
health aspects (51) 51
genotype (50) 50
microbiology (50) 50
mortality (48) 48
hepatitis c - complications (46) 46
hepatitis c virus (46) 46
hcv (45) 45
hepatitis c - drug therapy (44) 44
infected patients (44) 44
aids/hiv (43) 43
gastroenterology & hepatology (43) 43
research (43) 43
infections (42) 42
cohort studies (41) 41
therapy (41) 41
adolescent (40) 40
antiretroviral drugs (39) 39
antiretroviral therapy, highly active (39) 39
highly active antiretroviral therapy (38) 38
rna, viral - blood (38) 38
disease progression (37) 37
active antiretroviral therapy (36) 36
analysis (36) 36
hiv patients (36) 36
care and treatment (35) 35
ribavirin (35) 35
disease (34) 34
europe (34) 34
hepatitis c, chronic - drug therapy (34) 34
coinfection (33) 33
comorbidity (33) 33
hepacivirus - genetics (33) 33
hiv infections - epidemiology (33) 33
hiv-1 (33) 33
prevalence (31) 31
human immunodeficiency virus (30) 30
prospective studies (30) 30
epidemiology (29) 29
hepatitis c, chronic - complications (29) 29
ribavirin - therapeutic use (29) 29
virus diseases (29) 29
liver diseases (28) 28
tenofovir (28) 28
acquired immune deficiency syndrome--aids (27) 27
cirrhosis (27) 27
interferon (27) 27
liver (27) 27
medicine (27) 27
dosage and administration (26) 26
progression (26) 26
anti-hiv agents - adverse effects (25) 25
efficacy (25) 25
hiv-1 - drug effects (25) 25
hiv-infected patients (25) 25
interferon-alpha - therapeutic use (25) 25
medicine, general & internal (25) 25
time factors (25) 25
viruses (25) 25
anti-retroviral agents - therapeutic use (24) 24
hiv-1 - genetics (24) 24
research article (24) 24
fibrosis (23) 23
risk (23) 23
anti-hiv agents - administration & dosage (22) 22
cohort (22) 22
coinfection - drug therapy (22) 22
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
by Rodger, Alison J and Cambiano, Valentina and Bruun, Tina and Vernazza, Pietro and Collins, Simon and Degen, Olaf and Corbelli, Giulio Maria and Estrada, Vicente and Estrada, Vicente P and Geretti, Anna Maria and Beloukas, Apostolos and Raben, Dorthe and Coll, Pep and Antinori, Andrea and Nwokolo, Nneka and Rieger, Armin and Prins, Jan M and Prins, Jan and Blaxhult, Anders and Weber, Rainer and Van Eeden, Arne and Brockmeyer, Norbert and Brockmeyer, Norbert H and Clarke, Amanda and del Romero Guerrero, Jorge and Raffi, Francois and Bogner, Johannes R and Bogner, Johannes and Wandeler, Gilles and Gerstoft, Jan and Gutiérrez, Felix and Brinkman, Kees and Kitchen, Maria and Ostergaard, Lars and Leon, Agathe and Ristola, Matti and Jessen, Heiko and Jessen, Arne and Stellbrink, Hans-Jürgen and Phillips, Andrew N and Lundgren, Jens and Cobarsi, Patricia and Nieto, Aroa and Meulbroek, Michael and Carrillo, Antonia and Saz, Jorge and Guerrero, Jorge D.R and García, Mar Vera and Masiá, Mar and Robledano, Catalina and Leal, Lorna and Redondo, Eva G and Marquez, Rocio and Sandoval, Raquel and Viciana, Pompeyo and Espinosa, Nuria and Lopez-Cortes, Luis and Podzamczer, Daniel and Tiraboschi, Juan and Morenilla, Sandra and Antela, Antonio and Losada, Elena and Sewell, Janey and Kirk, Sarah and Knott, Alyson and Fernandez, Thomas and Gompels, Mark and Jennings, Louise and Ward, Lana and Fox, Julie and Lwanga, Julianne and Lee, Ming and Gilson, Richard and Leen, Clifford and Morris, Sheila and Clutterbuck, Dan and Brady, Michael and Asboe, David and Fedele, Serge and Fidler, Sarah and Potthoff, Anja and Skaletz-Rorowski, Adriane and Seybold, Ulrich and Roider, Julia and Ruzicic, Slobodan and Kümmerle, Tim and Lehmann, Clara and Bartel, Sindy and Hüfner, Anja and Rockstroh, Jürgen and Mohrmann, Karina and Boesecke, Christoph and Krznaric, Ivanka and Ingiliz, Patrick and Grube, Christina and Braun, Dominique and Günthard, Huldrych and Furrer, Hansjakob and Rauch, Andri and Schmid, Patrick and ... and PARTNER Study Grp and PARTNER Study Group
The Lancet, ISSN 0140-6736, 06/2019, Volume 393, Issue 10189, pp. 2428 - 2438
The level of evidence for HIV transmission risk through condomless sex in serodifferent gay couples with the HIV-positive partner taking virally suppressive... 
VIRAL LOAD | MEDICINE, GENERAL & INTERNAL | RNA | HETEROSEXUAL TRANSMISSION | BLOOD-PLASMA | SEMEN | PREVENTION | INFECTION | SERODISCORDANT COUPLES | HIV patients | Disease transmission | HIV (Viruses) | Gay couples | Risk factors | Therapy | Sexually transmitted diseases--STD | Prophylaxis | Sex | Risk | Partnerships | Infections | Phylogeny | Incidence | Mathematical analysis | Antiretroviral agents | Human immunodeficiency virus--HIV | Drug therapy | Anal sex | Antiretroviral drugs | Sexual behavior | Health risks | Exposure | Ribonucleic acid--RNA | Seroconversion | Antiretroviral therapy | Studies | Data collection | Gays & lesbians | Condoms
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Interview with Professor Jürgen Rockstroh, director of the Bonn University Clinic. Atazanavir in general practice
by Rockstroh, Jürgen
MMW Fortschritte der Medizin, ISSN 1438-3276, 04/2004, Volume 146 Spec No 1, p. 18
HIV Protease Inhibitors - adverse effects | Pyridines - administration & dosage | Drug Administration Schedule | Humans | Drug Approval | HIV Protease Inhibitors - administration & dosage | Oligopeptides - adverse effects | Pyridines - adverse effects | Atazanavir Sulfate | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Drug Therapy, Combination | Delayed-Action Preparations
Journal Article
Details down arrow
3. Interview mit Professor Jürgen Rockstroh, Oberarzt am Universitätsklinikum Bonn. Atazanavir in der Praxis
by Rockstroh, Jürgen
MMW Fortschritte der Medizin, ISSN 1438-3276, 04/2004, Volume 146, pp. 18 - 19
Journal Article
Details down arrow
4. Full Text Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv Cohort
by Stoll, Matthias and Kollan, Christian and Bergmann, Frank and Bogner, Johannes and Faetkenheuer, Gerd and Fritzsche, Carlos and Hoeper, Kirsten and Horst, Heinz-August and van Lunzen, Jan and Plettenberg, Andreas and Reuter, Stefan and Rockstroh, Jürgen and Stellbrink, Hans-Jürgen and Hamouda, Osamah and Bartmeyer, Barbara and ClinSurv Study Grp and ClinSurv Study Group and and the ClinSurv Study Group
PLoS ONE, ISSN 1932-6203, 09/2011, Volume 6, Issue 9, p. e23946
Background/Aim of the Study: The study aimed to determine the cost impacts of antiretroviral drugs by analysing a long-term follow-up of direct costs for... 
INDIVIDUALS | THERAPY | PRICE | DRUGS | EMTRICITABINE | BIOLOGY | INFECTION | STRATEGIES | REDUCE | LIFE | Anti-HIV Agents - pharmacology | Anti-HIV Agents - economics | Follow-Up Studies | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Drugs, Generic - economics | Reverse Transcriptase Inhibitors - pharmacology | Male | Drugs, Generic - therapeutic use | Protease Inhibitors - pharmacology | Drug Prescriptions - economics | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Protease Inhibitors - therapeutic use | Drugs, Generic - pharmacology | Reverse Transcriptase Inhibitors - economics | Protease Inhibitors - economics | Drug Therapy, Combination - economics | Drug Prescriptions - statistics & numerical data | HIV Infections - drug therapy | Cost Savings - statistics & numerical data | Germany | Cohort Studies | Highly active antiretroviral therapy | Medical research | Generic drugs | Protease inhibitors | Proteases | Analysis | Economic aspects | Medicine, Experimental | HIV (Viruses) | Health care | Drugs | Antiretroviral drugs | Therapy | Costs | Ritonavir | Medical treatment | Resource allocation | Medical services | Cost reduction | Data processing | Disease control | Antiretroviral therapy | Prescription drugs | Inhibitors | Taxes | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Taxation | Cost analysis | Cost engineering | Pharmaceuticals | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Trouble with bleeding: Risk factors for acute hepatitis C among HIV-positive gay men from Germany-A case-control study
by Schmidt, Axel J and Rockstroh, Jürgen K and Vogel, Martin and An der Heiden, Matthias and Baillot, Armin and Krznaric, Ivanka and Radun, Doris
PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 3, p. e17781
Objectives: To identify risk factors for hepatitis C among HIV-positive men who have sex with men (MSM), focusing on potential sexual, nosocomial, and other... 
SEXUALLY-TRANSMITTED INFECTION | COINFECTED PATIENTS | HETEROSEXUAL TRANSMISSION | SEMINAL PLASMA | INCREASE | MULTIDISCIPLINARY SCIENCES | HOMOSEXUAL-MEN | SEX | HCV | PREVALENCE | HUMAN-IMMUNODEFICIENCY-VIRUS | Multivariate Analysis | Acute Disease | Demography | HIV Seropositivity - complications | Humans | Middle Aged | Risk Factors | Hemorrhage - complications | Logistic Models | Male | Health Knowledge, Attitudes, Practice | Case-Control Studies | Cross Infection - complications | Germany - epidemiology | Young Adult | Hepatitis C - epidemiology | Adult | Hepatitis C - complications | Aged | Condoms | Homosexuality, Male - statistics & numerical data | Surveys | Infection | Sexual behavior | Therapeutics | HIV patients | Gay men | HIV (Viruses) | Hepatitis C virus | Risk factors | Homeopathy | Materia medica and therapeutics | Drugs | Nosocomial infection | Drug abuse | Sex | Outbreaks | Viruses | Sexual transmission | Infections | Epidemiology | Blood | Bleeding | Hepatitis | Gloves | Surgery | Human immunodeficiency virus--HIV | Drug use | Public health | Health risks | Regression analysis | Risk analysis | Disease transmission | Hospitals | Men | Rectum | Amphetamines | Cocaine | Hepatitis C | Health risk assessment | Sexual partners | HIV | Human immunodeficiency virus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Is Hepatitis C Virus Elimination in Well-Defined Patient Groups Possible?
by Jürgen Kurt Rockstroh
Clinical Infectious Diseases, ISSN 1058-4838, 05/2018, Volume 66, Issue 9, p. 1366
In May 2016, the World Health Assembly endorsed the Global Health Sector Strategy (GHSS) on viral hepatitis 2016–2021. The GHSS calls for the elimination of... 
Hepatitis | Health risks | Viruses | Hepatitis C virus | Hepatitis C | Public health
Journal Article
Details down arrow
7. Full Text Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
by Wyen, Christoph and Hendra, Heidy and Vogel, Martin and Hoffmann, Christian and Knechten, Heribert and Brockmeyer, Norbert H and Bogner, Johannes R and Rockstroh, Jürgen and Esser, Stefan and Jaeger, Hans and Harrer, Thomas and Mauss, Stefan and van Lunzen, Jan and Skoetz, Nicole and Jetter, Alexander and Groneuer, Christiane and Fätkenheuer, Gerd and Khoo, Saye H and Egan, Deirdre and Back, David J and Owen, Andrew and German Competence Network HIVAIDS and German Competence Network for HIV/AIDS and on behalf of the German Competence Network for HIV/AIDS
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 4/2008, Volume 61, Issue 4, pp. 914 - 918
Objectives The aim of this study was to investigate the frequency of CYP2B6 polymorphisms (according to ethnicity) and the influence of heterozygosity and... 
Pharmacogenetics | Drug disposition | Metabolism | Pharmacokinetics | NNRTIs | INFECTIOUS DISEASES | ALLELES | VARIANTS | drug disposition | MICROBIOLOGY | NEVIRAPINE | REGIMENS | INDIVIDUALS | GENE | EFAVIRENZ | pharmacokinetics | PHARMACOLOGY & PHARMACY | metabolism | HEPATOTOXICITY | pharmacogenetics | Multivariate Analysis | Oxidoreductases, N-Demethylating - genetics | Age Factors | Reverse Transcriptase Inhibitors - blood | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Male | Nevirapine - therapeutic use | Chromatography, High Pressure Liquid | Nevirapine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Polymerase Chain Reaction | Aged, 80 and over | Adult | Benzoxazines - blood | Female | Reverse Transcriptase Inhibitors - therapeutic use | Body Mass Index | Gene Frequency | European Continental Ancestry Group | Benzoxazines - therapeutic use | Polymorphism, Genetic | HIV Infections - drug therapy | Aged | African Continental Ancestry Group | Nevirapine - pharmacokinetics | Cytochrome P-450 CYP2B6 | Genotype & phenotype | Human immunodeficiency virus--HIV | Whites | Blacks | Bioavailability | Antiviral drugs | Polymorphism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe
by Ingiliz, Patrick and Martin, Thomas C and Rodger, Alison and Stellbrink, Hans-Jürgen and Mauss, Stefan and Boesecke, Christoph and Mandorfer, Mattias and Bottero, Julie and Baumgarten, Axel and Bhagani, Sanjay and Lacombe, Karine and Nelson, Mark and Rockstroh, Jürgen K and NEAT Study Grp and NEAT study group
Journal of Hepatology, ISSN 0168-8278, 2016, Volume 66, Issue 2, pp. 282 - 287
Graphical abstract 
Gastroenterology and Hepatology | HCV therapy | Spontaneous clearance | HIV-HCV coinfection | Acute hepatitis C | HCV reinfection | SVR | METAANALYSIS | MSM | PERSISTENCE | RISK | DRUG-USERS | SEXUALLY-TRANSMITTED INFECTION | HEPATITIS-C VIRUS | COLLABORATION | PEOPLE | EPIDEMIC | GASTROENTEROLOGY & HEPATOLOGY | Hepacivirus - isolation & purification | Communicable Disease Control - statistics & numerical data | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | HIV Infections - epidemiology | HIV Infections - virology | Humans | Middle Aged | Europe - epidemiology | Male | Coinfection - epidemiology | Incidence | Homosexuality, Male | Hepatitis C - epidemiology | Hepatitis C - virology | HIV Seropositivity - epidemiology | Adult | Female | HIV Infections - drug therapy | Hepatitis C virus | HIV (Viruses) | HIV patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
by DeJesus, Edwin and Rockstroh, Jürgen K, MD and Henry, Keith, MD and Molina, Jean-Michel, MD and Gathe, Joseph, MD and Ramanathan, Srinivasan, PhD and Wei, Xuelian, PhD and Yale, Kitty, MSc and Szwarcberg, Javier, MD and White, Kirsten, Prof and Cheng, Andrew K, MD and Kearney, Brian P, Prof and GS-236-0103 Study Team
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2429 - 2438
Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TREATMENT-NAIVE | PHARMACOKINETICS | RALTEGRAVIR | SAFETY | EFAVIRENZ | ADULTS | SINGLE-TABLET REGIMEN | PATIENTS 96-WEEK EFFICACY | COMBINATION | ADHERENCE | HIV-1 | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Atazanavir Sulfate | Adult | Female | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Antiretroviral drugs | Bone density | Pharmaceutical industry | Human immunodeficiency virus--HIV | Pneumonia | Laboratories | Ritonavir | Liver | Infections | Drug resistance | Hepatitis | Randomization | All terrain vehicles | Creatinine | Integrase | Data processing | Proteinase inhibitors | Behavior disorders | Ribonucleic acid--RNA | Patients | Cholesterol | Glomerular filtration rate | Inhibitors | Protease inhibitors | Interactive systems
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients
by Anadol, Evrim and Lust, Kristina and Boesecke, Christoph and Schwarze-Zander, Carolynne and Mohr, Raphael and Wasmuth, Jan-Christian and Rockstroh, Jürgen Kurt and Trebicka, Jonel
PLoS ONE, ISSN 1932-6203, 01/2018, Volume 13, Issue 1, p. e0191118
Introduction Combined antiretroviral therapy (cART) has improved survival in HIV-patients. While the first antiretrovirals, which became available in... 
TRANSIENT ELASTOGRAPHY | HIV | DIDANOSINE | MULTIDISCIPLINARY SCIENCES | DISEASE | NONCIRRHOTIC PORTAL-HYPERTENSION | HCV-COINFECTED PATIENTS | C VIRUS | ANTIRETROVIRAL THERAPY | VIRAL-HEPATITIS | PROGRESSION | Cross-Sectional Studies | Anti-HIV Agents - adverse effects | Humans | Middle Aged | HIV Infections - complications | Adult | Female | HIV Infections - drug therapy | Hepatitis C - complications | Male | Liver Cirrhosis - chemically induced | Highly active antiretroviral therapy | Complications and side effects | Liver diseases | Fibrosis | Physiological aspects | HIV patients | Risk factors | Drugs | Authorship | Liver | Viruses | Alcohol | Infections | Stavudine | Medical diagnosis | Hepatitis | Ultrasonic imaging | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Hepatology | Human immunodeficiency virus--HIV | Drug therapy | Hypertension | Antiviral agents | Internal medicine | Proteinase inhibitors | Exposure | Patients | Antiretroviral therapy | Medicine | Cirrhosis | Protease inhibitors | Didanosine | Acquired immune deficiency syndrome | AIDS | Human immunodeficiency virus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons
by Ryom, L and Boesecke, C and Gisler, V and Manzardo, C and Rockstroh, J. K and Puoti, M and Furrer, H and Miro, J. M and Gatell, J. M and Pozniak, A and Behrens, G and Battegay, M and Lundgren, J. D and Lundgren, Jens D and Ryom, Lene and Gatell, José M and Pozniak, Anton and Manzardo, Christian and Monforte, Antonella d'Arminio and Arribas, José and Battegay, Manuel and Clumeck, Nathan and Dedes, Nikos and Geretti, Anna Maria and Horban, Anzej and Katlama, Christina and McCormack, Sheena and Molina, Jean-Michel and Mussini, Cristina and Raffi, François and Reiss, Peter and Stellbrink, Hans-Jürgen and Behrens, Georg and Bower, Mark and Cinque, Paola and Collins, Simon and Compston, Juliet and Deray, Gilbert and de Wit, Stéphane and Fux, Christoph A and Guraldi, Giovanni and Mallon, Patrick and Martinez, Esteban and Marzolini, Catia and Papapoulos, Socrates and Du Pasquier, Renaud and Poulter, Neil and Williams, Ian and Winston, Alan and Rockstroh, Jürgen K and Puoti, Massimo and Boesecke, Christoph and Bhagani, Sanjay and Bruno, Raffaele and Konov, Svilen and Lacombe, Karine and Mauss, Stefan and Mendao, Luis and Peters, Lars and Rauch, Ani and Tural, Cristina and Furrer, Hansjakob and Miro, Jose M and Gisler, Valentin and Fätkenkeuer, Gerd and Kirk, Ole and Mocroft, Amanda and Morlat, Philippe and Volny-Anne, Alain and Mulcahy, Fiona and Katlama, Christine and Oprea, Cristiana and Youle, Mike and EACS Governing Board and the EACS Governing Board
HIV medicine, ISSN 1464-2662, 2016, Volume 17, Issue 2, pp. 83 - 88
BackgroundThe European AIDS Clinical Society (EACS) guidelines are intended for all clinicians involved in the care of HIV-positive persons, and are available... 
opportunistic infections | ART | HIV | comorbidities | HCV | EACS | antiretroviral treatment | HBV | Guidelines | Opportunistic infections | Comorbidities | Antiretroviral treatment | INFECTIOUS DISEASES | Immune Reconstitution Inflammatory Syndrome - prevention & control | Guidelines as Topic | Immune Reconstitution Inflammatory Syndrome - diagnosis | HIV Infections - epidemiology | Humans | Male | Viral Load | Drug Interactions | Societies, Medical | HIV Infections - diagnosis | Pregnancy Complications, Infectious - prevention & control | Post-Exposure Prophylaxis | Adult | Female | Pregnancy Complications, Infectious - diagnosis | Standard of Care | Comorbidity | AIDS-Related Opportunistic Infections - drug therapy | Europe - epidemiology | AIDS-Related Opportunistic Infections - diagnosis | CD4 Lymphocyte Count | Pre-Exposure Prophylaxis | Antiretroviral Therapy, Highly Active | Pregnancy | AIDS-Related Opportunistic Infections - prevention & control | Pregnancy Complications, Infectious - drug therapy | Immune Reconstitution Inflammatory Syndrome - drug therapy | HIV Infections - drug therapy | Antiviral agents | Liver diseases | Practice guidelines (Medicine) | HIV patients | Biological response modifiers | HIV (Viruses) | Highly active antiretroviral therapy | AIDS (Disease) | Drug therapy | Hepatitis C virus | Hepatitis C | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
by van Lunzen, Jan, Prof and Maggiolo, Franco, MD and Arribas, José R, Prof and Rakhmanova, Aza, MD and Yeni, Patrick, Prof and Young, Benjamin, MD and Rockstroh, Jürgen K, Prof and Almond, Steve, MMath and Song, Ivy, PhD and Brothers, Cindy, MSPH and Min, Sherene, MD
Lancet Infectious Diseases, The, ISSN 1473-3099, 2012, Volume 12, Issue 2, pp. 111 - 118
Summary Background Dolutegravir (S/GSK1349572) is a new HIV-1 integrase inhibitor that has antiviral activity with once daily, unboosted dosing. SPRING-1 is an... 
Infectious Disease | INTEGRASE INHIBITOR RALTEGRAVIR | INFECTIOUS DISEASES | EFFICACY | ELVITEGRAVIR | SAFETY | CREATININE | INFECTION | Virus Replication - drug effects | Benzoxazines - administration & dosage | HIV Infections - virology | Humans | Middle Aged | Male | RNA, Viral - blood | HIV Integrase Inhibitors - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Viral Load | Dose-Response Relationship, Drug | Young Adult | HIV-1 - physiology | Heterocyclic Compounds, 3-Ring - administration & dosage | Adult | Female | HIV Infections - drug therapy | Aged | HIV Infections - metabolism | Antiviral agents | Analysis | Product development | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights